IL134345A0 - Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon - Google Patents
Methods for treatment of patients afflicted with multiple sclerosis using consensus interferonInfo
- Publication number
- IL134345A0 IL134345A0 IL13434598A IL13434598A IL134345A0 IL 134345 A0 IL134345 A0 IL 134345A0 IL 13434598 A IL13434598 A IL 13434598A IL 13434598 A IL13434598 A IL 13434598A IL 134345 A0 IL134345 A0 IL 134345A0
- Authority
- IL
- Israel
- Prior art keywords
- multiple sclerosis
- methods
- treatment
- consensus interferon
- patients afflicted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/911,893 US6013253A (en) | 1997-08-15 | 1997-08-15 | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
PCT/US1998/014622 WO1999008702A1 (en) | 1997-08-15 | 1998-07-15 | Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon |
Publications (1)
Publication Number | Publication Date |
---|---|
IL134345A0 true IL134345A0 (en) | 2001-04-30 |
Family
ID=25431058
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13434598A IL134345A0 (en) | 1997-08-15 | 1998-07-15 | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon |
IL134345A IL134345A (en) | 1997-08-15 | 2000-02-02 | Use of Interferon Consensus in drug preparation, combination and pharmaceutical preparation that includes Interferon Consensus |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL134345A IL134345A (en) | 1997-08-15 | 2000-02-02 | Use of Interferon Consensus in drug preparation, combination and pharmaceutical preparation that includes Interferon Consensus |
Country Status (18)
Country | Link |
---|---|
US (1) | US6013253A (xx) |
EP (1) | EP1003546B1 (xx) |
JP (1) | JP3813440B2 (xx) |
KR (1) | KR100415636B1 (xx) |
CN (1) | CN1183963C (xx) |
AT (1) | ATE338563T1 (xx) |
AU (1) | AU741074B2 (xx) |
CA (1) | CA2299361C (xx) |
CY (1) | CY1107314T1 (xx) |
DE (1) | DE69835823T2 (xx) |
DK (1) | DK1003546T3 (xx) |
ES (1) | ES2267188T3 (xx) |
HK (1) | HK1030157A1 (xx) |
HU (1) | HU229045B1 (xx) |
IL (2) | IL134345A0 (xx) |
PT (1) | PT1003546E (xx) |
TW (1) | TW474817B (xx) |
WO (1) | WO1999008702A1 (xx) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030007972A1 (en) * | 1999-02-24 | 2003-01-09 | Edward Tobinick | Cytokine antagonists and other biologics for the treatment of bone metastases |
US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
US6982089B2 (en) | 1999-02-24 | 2006-01-03 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
US7214658B2 (en) * | 2004-07-06 | 2007-05-08 | Tact Ip, Llc | Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection |
US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
WO2003049761A1 (en) * | 2000-12-08 | 2003-06-19 | Neuronz Limited | Use of insuline-like growth factor-i for promoting remyelination of axons |
ATE435852T1 (de) | 2001-05-24 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
US7714020B2 (en) | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7605177B2 (en) | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7230167B2 (en) | 2001-08-31 | 2007-06-12 | Syngenta Participations Ag | Modified Cry3A toxins and nucleic acid sequences coding therefor |
SI1471974T1 (sl) * | 2002-02-06 | 2007-12-31 | Ares Trading Sa | Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih |
WO2004035086A2 (en) * | 2002-10-16 | 2004-04-29 | Hunter Samuel F | Method for treatment of demyelinating central nervous system disease using gm-csf |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
CA2553040A1 (en) * | 2004-02-02 | 2005-08-18 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
DE102004008168B4 (de) * | 2004-02-19 | 2015-12-10 | Voxeljet Ag | Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung |
EA012205B1 (ru) * | 2004-05-17 | 2009-08-28 | Арес Трейдинг С.А. | Гидрогелевые препараты интерферона |
BRPI0510526A (pt) | 2004-06-01 | 2007-10-30 | Ares Trading Sa | formulações lìquidas estabilizadas de interferon |
CA2567309A1 (en) | 2004-06-01 | 2005-12-15 | Ares Trading S.A. | Method of stabilizing proteins |
TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
BG66458B1 (bg) | 2005-03-21 | 2014-10-31 | Иван Иванов | Средство за конкурентно инхибиране на ендогенен гама интерферон |
EP1901769A2 (en) * | 2005-05-02 | 2008-03-26 | Avigen, Inc. | Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease |
BRPI0520498B8 (pt) | 2005-08-26 | 2021-05-25 | Ares Trading Sa | processo para fabricação de interferon beta humano recombinante glicosilado, e uso de um meio de cultura isento de soro |
AU2006286489B2 (en) * | 2005-09-01 | 2012-08-09 | Ares Trading S.A. | Treatment of optic neuritis |
JP2009537605A (ja) | 2006-05-24 | 2009-10-29 | メルク セローノ ソシエテ アノニム | 多発性硬化症を治療するためのクラドリビン・レジメン |
SI2234645T1 (sl) * | 2007-12-20 | 2012-07-31 | Merck Serono Sa | Formulacije peg interferon beta |
BG66517B1 (bg) | 2008-04-08 | 2016-02-29 | Tigo Gmbh | Супресор на ендогенния човешки гама - интерферон |
US9359421B2 (en) | 2008-04-08 | 2016-06-07 | Tigo Gmbh | Suppressor of the endogenous interferon-gamma |
WO2013008102A2 (en) | 2011-07-14 | 2013-01-17 | R.E.D. Laboratories N.V../ S.A. | Methods and compositions for evaluating and/or treating chronic immune diseases |
US10512672B2 (en) | 2013-07-18 | 2019-12-24 | Xalud Therapeutics, Inc. | Methods for the treatment of inflammatory joint disease |
BG67190B1 (bg) | 2017-03-29 | 2020-11-16 | Tigo Gmbh | Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5075222A (en) * | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
ES2103305T3 (es) * | 1989-11-29 | 1997-09-16 | Amgen Boulder Inc | Produccion de inhibidor de interleuquina-1 humana recombinada. |
AU7683391A (en) * | 1990-04-27 | 1991-11-27 | Upjohn Company, The | Modified interleukin-1 inhibitors |
AU660633B2 (en) * | 1990-10-17 | 1995-07-06 | Amgen, Inc. | Methods and compositions for the treatment of cell proliferation disorders |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5858355A (en) * | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
JP3693671B2 (ja) * | 1991-03-15 | 2005-09-07 | アムゲン インコーポレーテッド | ポリペプチドのpeg化 |
ES2142341T3 (es) * | 1992-04-30 | 2000-04-16 | Amgen Inc | Metodos de tratamiento de las enfermedades inducidas por la interleuquina-1 y el factor de necrosis tumoral. |
CZ291261B6 (cs) * | 1992-09-17 | 2003-01-15 | Amgen Inc. | Farmaceutická kompozice pro léčení nemocí zprostředkovaných interleukinem-1 |
US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
EP0701563A4 (en) * | 1993-03-08 | 1997-07-02 | Univ Pittsburgh | GENE TRANSFER FOR THE TREATMENT OF CONNECTIVE TISSUES IN A HOST MAMMAL |
CA2157758A1 (en) * | 1993-03-19 | 1994-09-29 | Louis Chedid | Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
FR2706772A1 (en) * | 1993-06-22 | 1994-12-30 | Vacsyn Sa | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
EP1090645B1 (en) * | 1994-02-08 | 2005-12-07 | Amgen Inc., | Oral delivery of chemically modified proteins |
-
1997
- 1997-08-15 US US08/911,893 patent/US6013253A/en not_active Expired - Lifetime
-
1998
- 1998-07-15 AT AT98933344T patent/ATE338563T1/de active
- 1998-07-15 DE DE69835823T patent/DE69835823T2/de not_active Expired - Lifetime
- 1998-07-15 WO PCT/US1998/014622 patent/WO1999008702A1/en active IP Right Grant
- 1998-07-15 KR KR10-2000-7001097A patent/KR100415636B1/ko not_active IP Right Cessation
- 1998-07-15 CN CNB988081520A patent/CN1183963C/zh not_active Expired - Fee Related
- 1998-07-15 EP EP98933344A patent/EP1003546B1/en not_active Expired - Lifetime
- 1998-07-15 ES ES98933344T patent/ES2267188T3/es not_active Expired - Lifetime
- 1998-07-15 AU AU83006/98A patent/AU741074B2/en not_active Expired
- 1998-07-15 CA CA002299361A patent/CA2299361C/en not_active Expired - Fee Related
- 1998-07-15 HU HU0002755A patent/HU229045B1/hu unknown
- 1998-07-15 IL IL13434598A patent/IL134345A0/xx active IP Right Grant
- 1998-07-15 DK DK98933344T patent/DK1003546T3/da active
- 1998-07-15 PT PT98933344T patent/PT1003546E/pt unknown
- 1998-07-15 JP JP2000509439A patent/JP3813440B2/ja not_active Expired - Lifetime
- 1998-07-29 TW TW087112465A patent/TW474817B/zh not_active IP Right Cessation
-
2000
- 2000-02-02 IL IL134345A patent/IL134345A/en not_active IP Right Cessation
-
2001
- 2001-02-16 HK HK01101141A patent/HK1030157A1/xx not_active IP Right Cessation
-
2006
- 2006-11-27 CY CY20061101704T patent/CY1107314T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2299361C (en) | 2009-09-29 |
CY1107314T1 (el) | 2012-11-21 |
DE69835823D1 (de) | 2006-10-19 |
HU229045B1 (en) | 2013-07-29 |
EP1003546B1 (en) | 2006-09-06 |
CN1183963C (zh) | 2005-01-12 |
KR100415636B1 (ko) | 2004-01-24 |
TW474817B (en) | 2002-02-01 |
AU741074B2 (en) | 2001-11-22 |
DE69835823T2 (de) | 2007-08-09 |
CN1267225A (zh) | 2000-09-20 |
ATE338563T1 (de) | 2006-09-15 |
HK1030157A1 (en) | 2001-04-27 |
HUP0002755A3 (en) | 2001-11-28 |
US6013253A (en) | 2000-01-11 |
WO1999008702A1 (en) | 1999-02-25 |
JP3813440B2 (ja) | 2006-08-23 |
IL134345A (en) | 2011-03-31 |
CA2299361A1 (en) | 1999-02-25 |
JP2001515047A (ja) | 2001-09-18 |
AU8300698A (en) | 1999-03-08 |
ES2267188T3 (es) | 2007-03-01 |
HUP0002755A2 (hu) | 2000-12-28 |
DK1003546T3 (da) | 2006-10-30 |
EP1003546A1 (en) | 2000-05-31 |
KR20010030563A (ko) | 2001-04-16 |
PT1003546E (pt) | 2006-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL134345A0 (en) | Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon | |
TW265265B (xx) | ||
HK1084862A1 (en) | Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject | |
CA2334267A1 (en) | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c | |
GR3032207T3 (en) | 2-Bromomelatonin in the therapy of sleep disorders | |
IL108114A0 (en) | Therapeutic potentiated interferon combination | |
MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
IL130785A0 (en) | Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with an autoimmune disease or chronic immune system disorder and pharmaceutical compositions containing the same | |
HK1015692A1 (en) | Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections | |
WO1999013894A3 (en) | Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c | |
MY119359A (en) | Use of consensus interferon for reducing the side effects of interferon treatment in viral hepatitis. | |
GEP19991514B (en) | Method for Treatment with Interferon | |
WO2003059334A3 (en) | Gemcitabine in the treatment of smallpox | |
AU8716001A (en) | Treatment of hepatitis c with thymosin and pegylated interferon | |
EP1908477A3 (en) | Combination of temozolomide and pegylated interferon-alpha for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted |